Kbc Group Nv Eagle Pharmaceuticals, Inc. Transaction History

Kbc Group Nv

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Feb 15, 2024	BUY	$26.42 - $47.12 $24,649 - $43,962	933 New	933 $25,000
Q2 2022 Feb 14, 2024	BUY	$41.26 - $51.35 $38,495 - $47,909	933 New	933 $41,000
Q2 2022 Jul 26, 2022	BUY	$41.26 - $51.35 $38,495 - $47,909	933 New	933 $41,000
Q2 2020 Aug 10, 2020	SELL	$43.24 - $55.02 $21,792 - $27,730	-504 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$34.37 - $60.07 $502,420 - $878,103	-14,618 Reduced 96.67%	504 $23,000
Q3 2019 Nov 07, 2019	BUY	$53.25 - $59.98 $644,325 - $725,758	12,100 Added 400.4%	15,122 $855,000
Q2 2019 Jul 30, 2019	SELL	$46.61 - $58.45 $692,391 - $868,274	-14,855 Reduced 83.1%	3,022 $0
Q3 2018 Nov 14, 2018	BUY	$66.65 - $83.86 $1.19 Million - $1.5 Million	17,877 New	17,877 $0

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.